This company is no longer active
Humanigen Dividends and Buybacks
Dividend criteria checks 0/6
Humanigen does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-19,721,848.7%
Buyback Yield
| Total Shareholder Yield | -19,721,848.7% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M
Aug 12Humanigen plunges 57% as trial for COVID-19 therapy fails
Jul 13Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy
Jul 06Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?
Oct 30
Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?
Jul 14Humanigen begins rolling submission for lenzilumab in COVID-19 in U.K.
Jun 14Humanigen submits lenzilumab COVID-19 EUA application to FDA
May 28Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy
May 05Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price
May 05We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon
Mar 31Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?
Feb 26Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19
Jan 29Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment
Jan 11We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth
Jan 04
Humanigen secures new U.S. patent for lenzilumab
Dec 28Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme
Dec 17Humanigen EPS misses by $0.16
Nov 11Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19
Nov 06Humanigen executes lenzilumab licensing deal in Asia for COVID-19
Nov 03Humanigen Dosing Phase 3 Covid Patients, And Other News: The Good, Bad And Ugly Of Biopharma
Nov 01Dosing underway in lenzilumab late-stage study in COVID-19
Oct 30Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19
Oct 29Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if HGEN.Q's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HGEN.Q's dividend payments have been increasing.
Dividend Yield vs Market
| Humanigen Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (HGEN.Q) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Biotechs) | 2.3% |
| Analyst forecast (HGEN.Q) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate HGEN.Q's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HGEN.Q's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate HGEN.Q's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as HGEN.Q has not reported any payouts.